Document:

Unassociated Document

    CONFIDENTIAL
TREATMENT REQUESTED BY GENTIUM S.p.A

     

     

     

    
      
        TECHNICAL
TRANSFER SERVICES AGREEMENT

      

    

    
      

      

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    
                                      
                                        
                                          	1.
      Parties:	 	
                                                  Patheon International A.G.
      (“Patheon”) 

                                                  Lindenstrasse
      14,

                                                  6340 Baar, 22079

                                                  Switzerland

                                                	 
      	
                                                  Gentium
      S.p.A. (“Gentium” or “Customer”)

                                                  Piazza
      XX Settembre, 2

                                                  Villa Guardia (Como)

                                                  Italy

                                                
	 	 	 	 	 
	2.
      Product:	 
      	Defibrotide
      (“Product”)	 
      	 
      
	 	 	 	 	 
	3.
      Subcontractor: 	 
      	
                                                  Patheon Italia
      S.p.A.

                                                  Via G.B. Stucchi n.110

                                                  Monza (MI) - Italy

                                                	 
      	 
      
	 	 	 	 	 
	4. Facility: 	 
      	
                                                  Patheon
      Italia S.p.A,

                                                  via Morolense 87,

                                                  Ferentino (FR) - Italy

                                                	 
      	 
      
	 	 	 	 	 
	
                                                  5. Contract:

                                                	 
      	
                                                  This
      document - including the Project Scope, Budget Summary, Standard Terms and
      Conditions for the Technical Transfer Services (“Terms and Conditions”) -
      when accepted by Customer shall become a contract binding on the parties
      (“Contract”).

                                                
	 	 	 
	
                                                  6.
      Description of
      Services, Payment and Currency: 

                                                	 
      	See
      Project Scope (Part A).	 
      	 
      
	 	 	 	 	 
	
                                                  7. Legal
      Terms:

                                                	 
      	
                                                  See
      Terms and Conditions (Part B).

                                                	 
      	 
      
	 	 	 	 	 
	
                                                  8. Effective
      Date:

                                                	 
      	
                                                  2
      February, 2009

                                                	 
      	 
      
	 	 	 	 	 
	
                                                  9. Term:

                                                	 
      	
                                                  From the Effective Date until
      completion by Patheon of the Technical Transfer Services
      (“Services”).

                                                
	 	 	 
	
                                                  10. Date:

                                                	 
      	
                                                  2
      February, 2009

                                                	 
      	 
      

                                        

                                      

                                    

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                	
                                        Patheon
      International A.G.

                                      	 	
                                        Gentium
      S.p.A.

                                      
	 
      	 
      	 	 
      	 
      
	
                                        By:

                                      	
                                        /s/ Aldo Braca

                                      	 	
                                        By:

                                      	
                                        /s/ Gary Gemignani

                                      
	 
      	 
      	 	 
      	 
      
	
                                        Name:

                                      	
                                        Aldo Braca

                                      	 	
                                        Name:

                                      	
                                        Gary
      Gemignani

                                      
	 
      	 
      	 	 
      	 
      
	
                                        Title:

                                      	
                                        President

                                      	 	
                                        Title:

                                      	
                                        Executive
      Vice President and Chief Financial
Officer

                                      

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

     

    
      CONFIDENTIAL

       

    

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    part a

     

    
      PROJECT
SCOPE

       

    

    
      1.  PROJECT
BRIEF

    

     

    Defibrotide
is a single-stranded polydeoxyribonucleotide extracted from porcine intestinal
mucosa. It has been shown that Defibrotide has protective effects on vascular
endothelial cells, particularly those of small vessels. Defibrotide has
antithrombotic, anti inflammatory and antiischaemic properties. After binding to
endothelial cells Defibrotide enhances fibrinolysis. These effects of
Defibrotide appear to be predominantly localized within the vascular bed, and
there appear to be  no significant effects on systemic
coagulation.

    

    Favorable
responses have been seen in previous clinical studies in about 45% of patients
treated with Defibrotide for the treatment of Severe Hepatic Veno-Occlusive
Disease (VOD).   There have also been no significant toxicities
related to the study drug in the majority of patients treated in previous
clinical studies.

    

    Recent
preclinical studies have demonstrated that Defibrotide used in conjunction with
Granulocyte Colony-Stimulating Factor (rhG-CSF) significantly increases the
number of Peripheral Blood Progenitor Cells (Stem cells). The benefit of this
increase in stem cells may be crucial for a variety of clinical indications,
including graft engineering procedures and gene therapy programs.

    

    Manufacturing
process steps: Solution Preparation, Filling, Inspection, Secondary
Packaging. Terminal sterilization is not required.

    

    Target
Production Site –The target site for the
production of the Defibrotide liquid vials will be the Sterile 2 suite at
the

    Ferentino
Site near Rome, Italy.

    

    Project
Timing – Validation Batches to be manufactured within Q4 2009. Patheon is
aware that timing is essential for the success of the Project; therefore Patheon
will use its very best efforts to procure the manufacturing of the validation
batches by the above mentioned timing, provided that this Contract, with respect
to the manufacturing services described herein, will be executed by 2nd February
2009.

     

    
      2.  KEY PRODUCT PARAMETER
OVERVIEW

    

     

    Batch
Size: -
approximately 40K vials

    

    Fill
Volume: - 2,5
ml

    

    Primary
Packaging components: – 3 ml vials (blown glass
vials, clear glass, Type I, 13 mm neck finish); West 4023/50 Gray stoppers, for
liquid, ready to sterilize; 13 mm flip off seals, aluminium feruled with
polypropylene colored cap. Sterile.

     

    
      3.  KEY MANUFACTURING SUPPLY
ASSUMPTION

    

     

    Health
and Safety evaluation – a preliminary EH&S toxicity classification of
the API has been procured by Patheon. It has been determined that the API
molecule is Category 2, on a scale of 1-4, 4 being the most potent. Category 2
products present no issue from a EH&S perspective.

    

    API

    
      	
              §  

            	
              It
      has been assumed that Gentium will provide the released API free issue to
      Patheon, that will require only an ID test (FT-IR
  test).

            

    

    
      	
              §  

            	
              API
      supplied at Room Temperature, with temperature recorder (data logger).
      Data logger information to be sent back to Gentium. API to be stored at
      Controlled Room Temperature (15 – 30
°C).

            

    

    
      	
              §  

            	
              Mixing
      of API lots for solution compounding is
allowed.

            

    

     

     

    CONFIDENTIAL

     

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 2 of
15

        
          

        

      

      
        
        

      

    

     

    
      	
              §  

            	
              API
      Container: The container closure system for the API Defibrotide is a
      multi-bag system, consisting of two LDPE bags within a multilayered
      aluminium bag, thermally sealed in a heat sealing machine.  The
      multilayered aluminium bag serves as a barrier to moisture transmission.
      Each container of API supplied with a side sample, for API incoming
      identity testing. Standard GMP and EH&S requirements will be adhered
      to throughout the whole process. Special care will be taken from operators
      during compounding, according to procedures supplied by
      Gentium.

            

    

    
      	
              §  

            	
              Patheon
      will receive the API pre-dispensed per each batch to be
      manufactured.

            

    

    
      	
              §  

            	
              API
      value: € *** per Kg.

            

    

    

    Finished
Product storage and shipment – Controlled room
temperature (15 – 30 °C). If required, Patheon will procure the use of a proper
and agreed number of Temperature recorders per each shipment. Costs of
Temperature recorders will be sustained by Gentium.

    

    Materials Procurement:
Components and Excipients

    
      	
              §  

            	
              Patheon
      will supply components (primary packaging materials and secondary
      packaging materials) and excipients for the manufacture from Patheon
      qualified suppliers (i.e., Patheon supplies
      everything excluding API). Should Gentium require Patheon to source any
      materials from Gentium’s specified suppliers, then these suppliers shall
      remain under the Quality audit control of Gentium unless an agreement is
      reached for Patheon to take on this
  responsibility.

            

    

    
      	
              §  

            	
              Components
      and excipients to be supplied by Patheon in accordance with client’s
      specifications. Subcontractor will issue formal Subcontractor
      specifications for each component following the Gentium’s component
      requirements. Each lot of incoming components will be sampled and tested
      according to the agreed
specifications.

            

    

    
      	
              §  

            	
              Listed
      below are the components for the solution
  preparation:

            

    

     

    
      
        
          
            
              	
                      Component

                    	
                      Reference
      to Standard Quality

                    	
                      Concentration
      per ml

                    
	
                      Sodium
      Citrate, Dihydrate

                    	
                      USP
      - EP

                    	
                      10
      mg

                    
	
                      Sodium
      hydroxide 1M or hydrochloric acid 1M

                    	
                      NF
      - EP

                    	
                      -

                    
	
                      API
      (Defibrotide)

                    	
                      Supplied
      from Gentium

                    	
                      80
      mg

                    

            

          

        

      

    

    

    Filter
Validation – It is assumed that all
the filters (0,22 μm and 0,45 μm) are fully validated by the filter supplier.
All the additional revalidation work for those filters will be performed by the
suppliers of the filters with costs being met by Gentium.

    

    Sealing
& Visual Inspection – According to the Subcontractor standard
process: filling stoppering and crimping will be performed in Class A/B. One run
of 100% visual inspection will be performed by manual or semi-automatic means
with qualified operators (defect characteristics and AQL limits to be
established and agreed).

    

    Cleaning
Validation – cleaning validation will
be required throughout the process, including dedicated and non dedicated
equipment i.e. general equipment, mixing and holding tanks, filling line.
Specific cleaning method is available at Gentium and will be
transferred.

    

    Batch
Release – Subcontractor (QP) performs the batch release to Gentium,
issuing Certificate of Analysis and Certificate of Compliance. The Batch Release
to the market has to be performed by Gentium.

    

    Product
Holding Time – The Holding Times of
the process has to be developed and validated, including the overnight storage
of the bulk solution.

    

    Silicon
Tubing – It is assumed that in case Silicon tubing (platinum cured) will
be used for transfer line, they will be used for at least 5
batches.

    

    Compatibility
Studies – It is assumed that
compatibility studies between the product and the following surfaces of the
process are available in Gentium: stainless steel, glass, PVC, Nylon, PE,
silicone, ceramic.

    

    Compatibility
and Stability data – Analytical tests for compatibility and stability
studies between the product and the stoppers are available
in  Gentium.

    

    In case
dedicated leachable and extractable studies will be required, those tests will
be performed by the suppliers of the stoppers with costs being met by client.
Quotation for such studies will be provided to Gentium.

     

     

    CONFIDENTIAL

     

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 3 of
15

        
          

        

      

      
        
        

      

    

     

    Process
Flow Description – Patheon assumes the
following production process, based on current information provided by
Gentium.

    

     

     

    Quality
Control

    
      	
              §  

            	
              All
      the analytical methods are fully validated; related protocols and reports
      are available at Gentium.

            

    

    
      	
              §  

            	
              Gentium’s
      Laboratory is available for the chemical analytical Transfer: the
      analytical results of three (3) released batches of Defibrotide liquid
      Product obtained in Gentium’s Lab (the Transferring lab) will be compared
      to those obtained in Subcontractor’s Lab (the Receiving Lab). When
      required additional analytical performance characteristics will be
      evaluated. Dedicated protocols and reports will be shared and
      issued.

            

    

    
      	
              §  

            	
              IPC
      and FP to be tested in accordance with Gentium specifications. It has been
      assumed that the testing is to standardised EP/USP requirements. Any
      client or product specific testing requirements would require a full
      assessment.

            

    

    
      	
              §  

            	
              It
      is assumed that Patheon will supply the following tests (IPC and FP).
      Analytical methods descriptions are already available (to date Gentium’s
      Reference “Scheda di analisi PF001/06 ed.
03”):

            

    

    IPC tests required as
follows:

    
      	
              o  

            	
              pH,
      Appearance, Density, Bioburden, Assay (the assay is not a stop test. To
      date the Method has not been
defined)

            

    

    Chemical
tests on FP required as follows:

    
      	
              o  

            	
              Appearance,
      Colour, pH, Volume in container

            

    

    
      	
              o  

            	
              ID
      (λ Maximum absorption)

            

    

    
      	
              o  

            	
              Mean
      Molecular weight, polydispersity index and fraction above 12 KDa by
      HPLC

            

    

    
      	
              o  

            	
              Nucleic
      Phosphorus: Optical Emission spectroscopy Identity and
    Assay

            

    

    
      	
              o  

            	
              Free
      Phosphorus: Ionic chromatography
Assay

            

    

    
      	
              o  

            	
              Free
      nucleic bases and other unknown impurities: HPLC
  Assay

            

    

    
      	
              o  

            	
              Particulate
      Matter in injection: USP <788> method
I

            

    

    Biological
tests on FP required as follows:

    
      	
              o  

            	
              Bacterial
      endotoxins test: As per USP <85> kinetic method
      (Turbidimetric)

            

    

    
      	
              o  

            	
              Sterility:
      As per USP <71>

            

    

     

     

    CONFIDENTIAL

     

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 4 of
15

        
          

        

      

      
        
        

      

    

     

    Secondary
Packaging

    
      	
              §  

            	
              Secondary
      packaging configuration, specifications and drawings for each secondary
      packaging component not yet defined by Gentium. As per Gentium request,
      Patheon makes the following proposal. This proposal is subject to review
      following receipt and discussion of the detailed secondary packaging
      requirements between the parties:

            

    

    o Vials: labeled by
automatic means

    
      o Carton: 1 carton
containing 10 labeled vials in the packaging tray and 1 leaflet packed by
automatic means.

    

    § Labeled
vials and 1 leaflet inserted into carton by automatic means

    § Batch
data automatically printed in line on the carton.

    o Box: 1 box containing
the cartons (i.e. 20, TBD).

    § Cartons
manually inserted into the box. Box labeling included (manual).

    o Shipping Box: 1
carton pallet containing the boxes (i.e. 100, TBD).

    § Boxes
manually inserted into the shipping box. Shipping Box labeling included
(manual).

     

    
      4.  TECHNOLOGY TRANSFER (TT)
COSTING ESTIMATES

    

     

    
      
        
          
            	
                    ITEM

                  	
                    TOTAL
      COST (€)

                  
	
                    API
      Health & Safety Evaluation

                  	
                    ***

                  
	
                    QA
      documentation preparation.

                    Review
      and supply of “Technical Data Pack” for Gentium’ regulatory submission.
      Provision of  all the information and data on components,
      packaging materials, drug product specifications and methods,
      manufacturing process, process validation, as well as Patheon’s relevant
      information (i.e.: drawings of material and personnel flows, differential
      pressures schemes, environmental control practices etc.  that
      are needed for the preparation of the regulatory
      documentation.

                    This
      work also covers preparation of Master Batch Record, Bill Of Materials,
      components specs and analytical methods.

                  	
                    
                      ***

                    

                  
	
                    Project
      controlling documentation – Technology transfer protocol and subsequent
      closure report.

                  	
                    
                      ***

                    

                  
	
                    Process
      Validation: protocol preparation, execution, QC testing and reporting.
      Stability/Registration/Process Validation batches (3 full scale Batches,
      secondary packaging excluded) (1)

                  	
                    
                      ***

                    

                  
	
                    Business
      / Project Management (10% of TT cost)(2)

                  	
                    Free
      of charge

                  
	
                    TOTAL

                  	
                    
                      ***

                    

                  

          

        

      

    

    
      	
              (1)  

            	
              This
      cost does not include vials price. Vials will be sold at the agreed unit
      price

            

    

    
      	
              (2)  

            	
              Patheon
      agrees to hold face to face or telephone meetings with Gentium at least
      once every two weeks to provide a general update on the status of the
      project and understand any key outstanding items.  Patheon will
      not charge Gentium for these meetings or for any follow-ups, outside of
      specific regulatory activities described in Section 5
    below.

            

    

     

    Technology Transfer cost is
charged at 40% up front payment in the form of a purchase order from
Gentium upon Patheon being awarded the project and then 20% on completion
of the feasibility batch and the remaining 40% on completion and submission to
Gentium of the Process Validation Report and the batch certificates of
analysis.

     

    
      5. 
REGULATORY SUPPORT
WORK

    

     

    Patheon
will procure by the Subcontractor  the assistance necessary to support
Gentium with their submissions. The scope and depth of regulatory support
procured by Patheon, based on data generated in course of performing the
Services, can be agreed upon depending on customer’s needs.

    An
example of the routine regulatory support is reported below:

    
      	
              §  

            	
              Customer
      provides Subcontractor with the list of information (i.e. list of CTD
      sections) they will include within the submission file. Complete list of
      information will be shared between the Parties in a separate
      document.

            

    

     

     

    CONFIDENTIAL

     

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 5 of
15

        
          

        

      

      
        
        

      

    

     

    
      	
              §  

            	
              Subcontractor
      will provide the Customer with the required information (i.e. protocols,
      reports, specification, CoA, executed batch record, etc.) and, upon
      request, also with summaries of such documents.  All documents
      will be provided preferably in English unless requested otherwise. When
      certified translations will be needed, costs will be borne by
      Gentium.

            

    

    
      	
              §  

            	
              Customer
      will write the filing and Subcontractor will review the sections
      pertaining to Subcontractor.

            

    

    Other
regulatory services:

    
      	
              §  

            	
              Regulatory
      administrative support (i.e. authentifiction / notarisation /
      certification/ apostille)

            

    

    
      	
              §  

            	
              Regulatory
      consulting to specific administrative requests (i.e. assessment and
      provision of regulatory guidance).

            

    

    

    Regulatory
work will be charged at €
***/hour.  Patheon will inform Gentium when regulatory
activities are being undertaken that will be billed.  It is Gentium’s
understanding that informal phone calls and simple requests will not be charged
for.

    In
addition to the Regulatory work hourly rate charge, Gentium will have to incur
all the costs pertaining to documents legalization (i.e. authentification,
notarisation, certification, apostille) or for any other relevant regulatory
activity. Patheon will inform Gentium when such costs will be
billed.

     

    
      6. 
STABILITY
TESTING PROGRAMME

    

     

    If
required Patheon can  procure the storage and testing services in
accordance with an agreed protocol and ICH guidelines. A typical charge per
sample time point is indicated below. This fee is to be confirmed upon receipt
of the full stability testing analysis required.

    

    Charge
per time point is €
1,800.

     

    
      7. 
PRICING
INDICATION

    

     

    
      
        
          
            
              
                
                  	
                          Batch
      size

                          (#
      vials)

                        	
                          Manufacturing

                          Conversion
      Price

                        	
                          Components

                          cost

                        	
                          Secondary
      packaging

                          Conversion
      Price

                        	
                          Total
      unit price (**)

                        
	
                          *** vials

                        	
                          €*** /
      vial

                        	
                          €***
      / vial

                        	
                          €***
      / vial

                        	
                          €***
      /
vial

                        

                

              

            

          

        

      

    

     

    
      	
               
      

            	
              (**): This
      price doesn’t include the Secondary packaging components cost. It will be
      evaluated once defined the Secondary packaging materials
      specification.

            

    

     

    
      8.  FEASIBILITY
ASSESSMENT

    

     

    In view
of the commercial manufacturing services to be potentially supplied by Patheon
on behalf of the Customer, an assessment of the feasibility of the manufacturing
process of the Product, with respect to the fixtures and fittings incorporated
into the Facility, is needed. To this aim, Patheon requested to the
Subcontractor, upon the Customer’s consent, to perform the activities detailed
in this Section 8.

     

    The
Parties agree that the costs of such assessment will be directly invoiced by the
Subcontractor to the Customer. Each Subcontractor invoice will be due and
payable within 45 days of the date of the relevant invoice.

     

    8.1.  Feasibility
activities

     

    
      
        
          
            	
                    ITEM

                  	
                    TOTAL
      COST (€)

                  
	
                    [Analytical
      Methods Transfer/Validation]:

                    Micro
      (3, validation):

                    Bioburden, BET and
sterility

                  	
                    ***

                  
	Chemical
      (6): 

                    Mean molecular weight,
      polydispersity and fraction above 12 (transfer)

                    Identification, UV
      (transfer)

                    Nucleic P
      (validation)

                    Free P
      (transfer)

                    Free nucleic bases and other
      unknown impurities (transfer)

                    Particulate
      matter in inj (transfer)

                  	 
	
                    Cleaning
      process Validation – Cleaning method transfer & entire equipment train
      – protocol preparation, execution, QC testing and
    reporting.

                  	
                    ***

                  
	
                    Validation
      master plan & Sterility assurance / re-qualification work (autoclave /
      tunnel)

                  	
                    ***

                  
	
                    One
      Feasibility batch (full scale) - protocol preparation, execution, QC
      testing – vials not for human use (for stability purpose) (1)

                  	
                    ***

                  
	
                    Filter
      Validation

                  	
                    ***

                  
	
                    TOTAL

                  	
                    ***

                  

          

        

      

    

     

    (1) In
case more than one feasibility batch will be needed, each feasibility batch will
be charged to Gentium at the above mentioned price.

     

    (2) Face
to face or telephone meetings with Gentium will be held at least once every two
weeks to provide a general update on the status of the project and understand
any key outstanding items.  No additional costs will be charged to
Gentium for these meetings or for any follow-ups.

     

    The Feasibility Activities
cost is charged at 40% up front payment in the form of a purchase order from
Gentium upon Patheon being awarded the project and then 20% on completion
of the feasibility batch and the remaining 40% on completion and submission to
Gentium of the Process Validation Report and the batch certificates of
analysis.

     

     

    CONFIDENTIAL

     

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 6 of
15

        
          

        

      

      
        
        

      

    

     

    8.2.   Media
Fill

     

    Up to 3
media fills runs may be performed using the specific parameters for the batch
manufacturing. Gentium will be charged fully for each of the Media Fill run
Subcontractor will have to manufacture dedicated to the project.

    

    Charge
per each Media Fill Run is €
***

    

    In case
it transpires that Subcontractor has data applicable to cover the Defibrotide
process, so that Subcontractor won’t need to manufacture any Media fill run
dedicated to the project, then only 25% of the media fill runs charges will be
levied on Gentium (€ ***).

     

    8.3.   Capex
Proposal and Costing

     

    All CapEx
items will be agreed with Gentium against specific “User Requirements” and will
be purchased by the Subcontractor. Gentium will contribute at “cost plus 9%.” The handling
fee is to reflect Subcontractor’s time and money for developing the equipment
specifications, negotiation with suppliers and procurement of the equipment. The
handling fee charge is not included in the below mentioned prices.

    

    The
capital proposal is subject to review, following technical discussion between
the Subcontractor and Gentium on the proposed assumptions and process
scheme.

    

    Gentium
will provide Subcontractor with a Purchase Order for the overall Capital cost
(relating Production CapEx and QC CapEx, as described below) upon Patheon being
awarded the project. Such costs will be invoiced as follows:

    
      	
              ·  

            	
              Equipments
      costs: 80% upfront - remaining 20% on delivery of the
  tanks

            

    

    
      	
              ·  

            	
              Qualification
      costs: 100% at the beginning of the qualification
    activities

            

    

    
      	
              ·  

            	
              Handling
      fee costs: 100% on delivery of the
tanks.

            

    

    
      	
              ·  

            	
              Contingency
      costs: only if / when necessary

            

    

    Secondary
Packaging CapEx will be charged at the beginning of the Secondary Packaging
Transfer activities.

     

     

    CONFIDENTIAL

     

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 7 of
15

        
          

        

      

      
        
        

      

    

     

    Supplier
quotations / invoices can be provided if / when necessary, including multiple
competing bids if available. All purchases would be clearly discussed and
defined with Gentium prior to purchase and supported by supplier
proposals.

     

    
      	
              §  

            	
              Production CAPex: The
      following items are required for the manufacture of Defibrotide
      Batches.

            

    

     

    
      
        
          
            	
                    ITEM

                  	
                    TOTAL
      COST (€)

                  
	
                    Bosch
      filling machine change parts – contact parts -

                  	
                    ***

                  
	
                    Piping

                  	
                    ***

                  
	
                    Software
      modifications and electric works

                  	
                    ***

                  
	
                    2 x
      100 liters stainless steel tanks

                  	
                    ***

                  
	
                    Small
      equipment for solution preparation (glass containers,
      stirrers)

                  	
                    ***

                  
	
                    Dedicated
      equipment installation and qualification work - protocol preparation,
      execution and reporting, samples.

                  	
                    ***

                  
	
                    Subtotal

                  	
                    ***

                  
	
                    Contingency
      (10%)

                  	
                    ***

                  
	
                    TOTAL

                  	
                    ***

                  

          

        

      

    

     

    It is
assumed that dedicated tanks and transfer lines are required.

    

    
      	
              §  

            	
              QC CAPex: The following
      items are required for the Analytical Testing of Defibrotide Batches
      (Gentium’s Ref. Method PF001/06 ed. 03: PF001/06_06; PF001/06_07;
      PF001/06_08; PF001/06_11).

            

    

    

    
      
        
          
            
              	
                      ITEM

                    	
                      TOTAL
      ESTIMATED COST (€)

                    
	
                      Ionic
      chromatograph Metrohm 761 compact IC

                      (Ref.
      PF001/06_08)

                    	
                      ***

                    
	
                      Software
      modification

                      (Ref.
      PF001/06_06)

                    	
                      ***

                    
	
                      Lamp
      and if necessary works on the equipment already in house (AA Perkin Elmer)
      (1)

                      (Ref.
      PF001/06_07)

                    	
                      ***

                    
	
                      Equipment
      installation and qualification

                    	
                      ***

                    
	
                      Subtotal

                    	
                      ***

                    
	
                      Contingency
      (10%)

                    	
                      ***

                    
	
                      TOTAL

                    	
                      ***

                    

            

          

        

      

    

     

    
      	
               
      

            	
              (1):
      For the transfer of the release test ”Nucleic Phosphorus, Optical Emission
      spectroscopy Identity and Assay (Gentium’s Ref. Method PF001/06 ed. 03:
      PF001/06_07)” Subcontractor is not equipped with the ICP instrument, so
      Subcontractor proposed the following two
  options:

            

    

    
      	
              o  

            	
              Option # 1: Transfer of
      the current Gentium’s method (Plasma). In that case Subcontractor will
      have to purchase the ICP equipment, at the cost (approx. € ***) to be met
      by client.

            

    

    
      	
              o  

            	
              Option # 2: Validation
      of a new method (Graphite Furnace). In that case Subcontractor will have
      to adapt the equipment already in house (AA Perkin Elmer) with a new lamp
      with cost to be met by client (approx. €
***).

            

    

    

    Gentium
agreed on the above Option # 2 and the relevant cost has been included in the
above capital table. In case it will transpire that the equipment already in
house don’t have the sensitivity necessary for the analysis, Gentium will have
to re-evaluate the Option # 1 or the possibility to use a third party
laboratory.

     

     

    CONFIDENTIAL

     

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 8 of
15

        
          

        

      

      
        
        

      

    

     

    
      	
              §  

            	
              Secondary Packaging CAPex:
      The Secondary packaging CAPex will be evaluated once Gentium will
      define the specification of the Secondary packaging configuration. As
      follows the capital estimation costs, limited to the assumption
      made:

            

    

     

    
      
        
          
            	
                    ITEM

                  	
                    TOTAL
      COST (€)

                  
	
                    Samples
      for packaging configuration set-up

                  	
                    ***

                  
	
                    Subtotal

                  	
                    ***

                  
	
                    Contingency
      (10%)

                  	
                    ***

                  
	
                    TOTAL

                  	
                    ***

                  

          

           

        

      

    

     

    CONFIDENTIAL

     

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 9 of
15

        
          

        

      

      
        
        

      

    

     

    part b

     

    standard terms and
conditions for technical transfer services

    

    
      	
              1.

            	
              Services:

            

    

    
      	
               
      

            	
              (a)

            	
              Patheon
      hereby agrees to procure the performance of the Technical Transfer
      Services described in the Project Scope (“Services”), in accordance with
      the Specifications provided by the Customer, the current Good
      Manufacturing Practices (“cGMPs”) and all the other conditions provided in
      this Contract. The Customer hereby agree that Patheon may subcontract to
      its Affiliate, Patheon Italia S.p.A (“Subcontractor”), any Services under
      this Contract. In such case, Customer will have a right of access to the
      relevant Subcontractor’s Facility for auditing purposes. It is understood
      that Patheon shall enter into an agreement with its Affiliate that
      contains any terms necessary to ensure that Patheon meets its obligations
      under this Contract. For avoidance of doubt the subcontracting of any
      Services hereunder to the Subcontractor by Patheon shall not relieve
      Patheon of, and Patheon shall remain solely liable, vis-a-vis the Customer,
      for its obligations under this Contract. Given the foregoing the Parties
      hereby agree that the Services will be performed at the facility, owned
      and operated by Patheon Italia S.p.A, that is located at via Morolense 87,
      Ferentino (FR) - Italy (“Facility”).

              
                For
      the purposes of this Contract, the term Affiliate means any corporation
      which, directly or indirectly through one or more intermediaries, controls
      or is controlled by or is under common control with such party and, for
      the purpose of this definition, “control” means the ownership of shares
      carrying at least a majority of the votes in respect of the election of
      the directors of a
corporation.

              

            

    

    
      
      

    

    
      	
               
      

            	
              (b)

            	
              Parties
      must agree in writing on changes, deletions or additions to the Services
      (“Changes”).

            

    

    
      	
               
      

            	
              (c)

            	
              Minor
      Changes shall be confirmed by electronic mail, facsimile or other written
      document.  Significant Changes (such as a request by the
      Customer to change the Project Scope) shall be confirmed by a Change of
      Scope Agreement, which shall be agreed to by both
  parties.

            

    

    
      	
               
      

            	
              (d)

            	
              In
      the event the Customer has more than one option in relation to a
      particular Service (as written in the Project Proposal or within a Change
      of Scope as the case may be) then the Customer shall confirm in writing
      which option it wishes Patheon to perform prior to the commencement of the
      relevant Service to which the option relates. The Customer shall be
      charged the fee quoted for the option
taken.

            

    

    

    
      	
              2.

            	
              Payment:

            

    

    A.      Payment

    
      	
               
      

            	
              (a)

            	
              Customer
      shall pay Patheon for the Services as outlined in Part A of this Contract
      and for any agreed Changes which shall be invoiced separately at the fees
      quoted by Patheon. It is agreed upon between the Parties that the Services
      detailed in Section 8 of Part A of this Contract, will be invoiced to the
      Customer directly by the
Subcontractor.

            

    

    
      	
               
      

            	
              (b)

            	
              If
      Customer causes any delay to Patheon’s provision of Services for reason
      within its control (such as a delay in responding to a Patheon and/or
      Subcontractor inquiry or a delay in the delivery of the active
      pharmaceutical ingredient (“API”)), then Patheon shall be entitled to
      charge the Customer for any additional costs incurred in the provision of
      the Services as a result of the delay. In addition to the foregoing,
      should the delay in delivery the API cause the postponement or the
      cancellation of any batch of Product, Section 5(f) will be
      applied.

            

    

    
      	
               
      

            	
              (c)

            	
              Each
      Patheon invoice shall be due and payable within 45 days of the date of the
      relevant invoice. All amounts mentioned in this Contract will be deemed
      mentioned or specified in Euros.

            

    

    
      	
               
      

            	
              (d)

            	
              In
      no event, complaints or objections to the amount of the invoices or
      related to the Services will suspend the payment obligations
      of  the Customer. Interest on past due accounts will accrue at
      an annual rate of  eight percent per annum
  (8%).

            

    

    

    
      	
              3.

            	
              Supply
      of API and Materials:

            

    

    
      	
               
      

            	
              (a)

            	
              Customer
      shall, at its expense, supply Patheon, at the agreed Facility, with
      sufficient quantities of the API to be used in performing the
      Services.

            

    

    
      	
               
      

            	
              (b)

            	
              All
      materials required to perform the Services (“Materials”) shall be
      purchased by Patheon. If Materials ordered by Patheon in order to carry
      out the Services are not used in performing the Services, then to the
      extent Patheon’s other customers cannot utilize such Materials, the
      Customer shall pay to Patheon the costs for such Materials (including all
      costs incurred by Patheon in connection with the purchase and handling of
      such Components).

            

    

    
      
        	
                 
      

              	
                (c)

              	
                In
      the event that Patheon is required to procure any product from specified
      suppliers indicated by the Customer, in order to complete the Services,
      Customer acknowledges that all such purchases shall be made by Patheon on
      behalf of the Customer and that Patheon shall assume absolutely no
      responsibility or liability whatsoever with respect to such
      product.

              

      

    

     

     

    CONFIDENTIAL

     

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 10
of 15

        
          

        

      

      
        
        

      

    

    
       

      
        	
                 
      

              	
                (d)

              	
                If applicable, Patheon and
      the Customer will cooperate and provide such assistance to each other as
      may be reasonably necessary to permit the import of the API and other
      materials into the country where the Services will be
      performed.

              

      

       

      4.   Equipment:

    

    
      
        	
                 
      

              	
                (a)

              	
                In order to perform the
      Services, certain capital expenditures are necessary in respect of Capital
      Equipment required to be acquired and installed at Facility located at via
      Morolense 87, Ferentino (FR), Italy; therefore, the Customer hereby agree
      to deliver to Subcontractor the estimated amount, as better detailed in
      the Part A (Section 8) above, in respect of purchasing the Capital
      Equipment. It is understood that, should additional capital expenditures
      be necessary in order to carry out the Services, the Parties will jointly
      determine the revised aggregate amount contributable by the
      Customer.

              

      

      
        	
                 
      

              	
                (b)

              	
                All capital expenditures for
      the purchasing of the Capital Equipment shall be paid, as outlined in Part
      A of this Contract, by the
Customer.

              

      

      
        	
                 
      

              	
                (c)

              	
                The Customer shall have
      legal ownership of the Capital Equipment, with the exception
      of any software upgrade and any structural modifications to the
      Subcontractor’s existing lines and will assign such Capital Equipment to
      Subcontractor for its use.

              

      

      
        	
                 
      

              	
                (d)

              	
                Patheon shall be responsible
      for the costs and expenses of routine maintenance and servicing of the
      Capital Equipment, so long as the Capital Equipment remains at the
      Facility. Customer shall be responsible for the cost of non-routine
      maintenance and servicing of the Capital Equipment (such as major repairs
      and parts replacement).

              

      

       

    

     5.   Termination,
Cancellation and Postponement:  

    
      	
               
      

            	
              (a)

            	
              Either
      party may terminate this Contract if the other party is in material breach
      of any provisions of this Contract and the other party fails to remedy
      such breach within 30 days of the date of notice of such breach by the
      non-breaching party.

            

    

    
      	
               
      

            	
              (b)

            	
              Customer
      may terminate this Contract immediately for any business
      reason.

            

    

    
      	
               
      

            	
              (c)

            	
              Any
      re-scheduling of any part of the Services beyond 120 days requested by
      Customer shall, at Patheon’s option, be deemed to be a termination of the
      Contract.

            

    

    
      	
               
      

            	
              (d)

            	
              If
      the Customer terminates the Contract for any business reason or if Patheon
      terminates the Contract because of: (i) Customer’s failure to cure any
      default within the 30 day notice period; or (ii) Customer rescheduling any
      part of the Services beyond the 120 days, then Customer shall pay to
      Patheon:

            

    

     

    - any fees
and expenses due to Patheon for the Services rendered up to the date of
termination;

    - all
actual costs incurred by Patheon to complete activities associated with the
termination and close of the Services rendered up to the date of termination;
and

    - any
additional costs incurred by Patheon in connection with the Services that are
required to fulfill applicable regulatory and contractual
requirements;

    - the cost
of all materials (to the extent that such materials cannot be utilized for other
Patheon’s customers) and equipment which were purchased or maintained by Patheon
in contemplation of the Services as outlined in the Project Scope prior to
notice of termination being given (to the extent such equipment cannot be
utilized by Patheon’s other customers). In addition to the foregoing, Customer
shall satisfy the purchase price payable pursuant to Patheon's orders with
suppliers of materials and equipment, provided such orders were made by Patheon
in reliance on Services and they are not subject to cancellation without
penalty.

    
      
        	 	(e)	
                Customer
      shall arrange for the pickup from the Facility of all materials and
      supplies owned by Customer within 20 business days after the earlier of
      the termination or expiration of this Contract. Patheon shall charge a
      thirty Euro (€30.00) per pallet space per month storage fee for all
      materials, supplies and Products stored at the Facility after twenty
      business day following the termination of the Contract.

              
	
                 
      

              	
                (f)

              	
                In
      the event of termination, cancellation or postponement by the Customer
      within 60 calendar days of the due start date of manufacture of any batch
      of Product, for whatever reason, the Customer agrees to pay to Patheon a
      sum equal to 25% of the fees quoted for such manufacturing Services in
      Part A of this Contract.  In the event of termination,
      cancellation or postponement by Customer within 30 calendar days of the
      due start date of manufacture of any batch of Product, for whatever
      reason, the Customer agrees to pay to Patheon a sum equal to 50% of the
      fees quoted for such manufacturing Services in Part A of this
      Contract.  If termination, cancellation or postponement is
      within 15 calendar days of the due start date of manufacture of any batch
      of Product, the Customer agrees to pay a sum equal to 75% of the fees
      quoted for such manufacturing Services in Part A. If work is stopped
      within 5 working days of the week of manufacture of any batch of Product,
      for whatever reason, the Customer agrees to pay a sum equal to 90% of the
      fees quoted in Part A.

              

      

    

     

     

    CONFIDENTIAL

     

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 11
of 15

        
          

        

      

      
        
        

      

    

     

    6.      Intellectual
Property:

    
      	
               
      

            	
              (a)

            	
              The
      term “Intellectual Property” includes, without limitation, rights in
      patents, patent applications, formulae, trade-marks, trade-mark
      applications, trade-names, trade secrets, inventions, copyright,
      industrial designs and know-how.

            

    

    
      	
               
      

            	
              (b)

            	
              For
      the term of this Contract, Customer hereby grants to Patheon and to the
      Subcontractor, a non-exclusive, paid-up, royalty-free, non-transferable
      license of Customer’s Intellectual Property which Patheon must use in
      order to perform the Services.

            

    

    
      	
               
      

            	
              (c)

            	
              Patheon
      covenants, represents and warrants that, all Intellectual Property
      generated or derived in the course of performing the Services, to the
      extent it is specific to the development, manufacture, use and sale of the
      Customer’s Product that is the subject of the Services, shall be the
      exclusive property of Customer.

            

    

    
      	
               
      

            	
              (d)

            	
              All
      Intellectual Property generated or derived by Subcontractor in the course
      of performing the Services which are not specific to, or dependent upon,
      Customer’s Product and which have application to manufacturing processes
      or formulation development of drug products or drug delivery systems shall
      be the exclusive property of Subcontractor.  Patheon
      hereby warrants to Customer, a non-exclusive, paid-up, royalty-free,
      transferable license of such Intellectual Property which Customer may use
      for the manufacture of Customer’s
Product.

            

    

    

    
      	
              7.     

            	
              Indemnity:

            

    

    
      	
               
      

            	
              A.   Indemnification by
      Customer

            

    

    Subject
to Sections 7B and 7C(c), Customer shall defend, indemnify and hold Patheon, its
Affiliates and their respective directors, officers, employees and agents
(collectively, "Patheon Indemnitees") harmless from and against any and all
third-party actions, causes of action, costs (including reasonable legal fees),
claims, damages, liabilities and expenses (collectively, “Losses”) relating to
or arising from:

    
      	
              ·  

            	
              the
      distribution of the Customer’s Product or the use of the Customer’s
      Product by patients either as part of or outside of the scope of any
      clinical trials;

            

    

    
      	
              ·  

            	
              the
      performance of the Services in accordance with the terms of this
      Contract;

            

    

    
      	
              ·  

            	
              any
      misrepresentation, negligence or willful misconduct by Customer or any of
      its affiliates and their respective directors, officers, employees and
      agents (collectively,  "Customer
  Indemnitees");

            

    

    
      	
              ·  

            	
              any
      breach by the Customer of the Customer's obligations or warranties under
      this Contract; or

            

    

    
      	
              ·  

            	
              any
      claim of infringement or alleged infringement of any third party's
      intellectual property rights in respect of the Customer’s
      Product.

            

    

    
      	
               
      

            	
                 
      This indemnity shall not apply to the extent that such Losses
      are:

            

    

    
      	
              ·  

            	
              determined
      to have resulted from gross negligence or willful misconduct of
      Patheon;

            

    

    
      	
              ·  

            	
              determined
      that Patheon has failed to manufacture and test the Product in compliance
      with the Customer’s Specifications, cGMPs and the terms of this Contract;
      or

            

    

    
      	
              ·  

            	
              for
      which Patheon is obligated to indemnify the Customer Indemnitees pursuant
      to Section 7B.

            

    

    
      	
               
      

            	
              B.    Indemnification by
      Patheon

            

    

    Subject
to Sections 7A and 7C(c), Patheon shall defend, indemnify and hold the Customer
Indemnitees harmless from and against any and all Losses resulting from,
relating to or arising from the breach by Patheon of its obligations or
warranties under this Contract except to the extent that such Losses
are:

    · determined
to have resulted from gross negligence or willful misconduct of Customer;
or

    · for which
Customer is obligated to indemnify the Patheon Indemnitees pursuant to Section
7A.

    
      
        	
                 
      

              	
                C.    Limitation
      of Liability

              

      

    

    
      	
               
      

            	
              (a)  If
      any part of the Services procured by Patheon are not materially performed
      in accordance with the Customer’s Specifications, the cGMPs and the terms
      of this Contract, then Customer's sole remedy shall be to request Patheon
      to:

            

    

    · repeat
that part of the Service at Patheon’s costs, provided that Customer provides the
API; or

    · reimburse
Customer for the price for that part of the Service, excluding the cost of the
API.

    
      	
               
      

            	
              (b)  Under
      no circumstances whatsoever shall Patheon reimburse Customer for the cost
      of the API.

            

    

    
      	
               
      

            	
              (c)  Under
      no circumstances whatsoever shall either party be liable to the other in
      contract, tort, negligence, breach of statutory duty or otherwise for any
      loss of profits, of production, of anticipated savings, of business or
      goodwill or for any liabilities, damages, costs or expenses of any kind
      incurred by the other party of an indirect or consequential nature,
      regardless of any notice of the possibility of such
    damages.

            

    

    
      
        	
                 
      

              	D.    No
Warranty

      

    

    PATHEON
MAKES NO WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, BY FACT OR LAW,
OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS CONTRACT.  PATHEON MAKES
NO WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR WARRANTY OF MERCHANTABILITY
IN RESPECT OF THE CUSTOMER’S PRODUCT.

     

     

    CONFIDENTIAL

     

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 12
of 15

        
          

        

      

      
        
        

      

    

     

    8.      Regulatory
Filings:

    
      	
              (a)

            	
              Customer
      shall have the sole responsibility for filing of all documents with the
      applicable regulatory authority (such as the United States Food and Drug
      Administration (“FDA”), the Medicines and Healthcare Products Regulatory
      Agency ("MHRA") or the European Medicine Evaluation Agency (collectively
      the “Regulatory Authority”) and to take any other actions that may be
      required for the receipt of approval from the Regulatory Authority for the
      commercial manufacture of the Customer’s
  Product.

            

    

    
      	
              (b)

            	
              Where
      documents generated by Subcontractor in relation to the Services are to be
      filed by the Customer with any Regulatory Authority and such filing is
      liable to cause Subcontractor to be scrutinized by such Regulatory
      Authority or the filing thereof may create the possibility of a Regulatory
      Authority audit, inspection or review of Subcontractor then, at least 21
      days prior to filing any such documents with the Regulatory Authority,
      Customer shall provide Subcontractor with a copy of the documents
      incorporating such data so as to give Subcontractor the opportunity to
      verify the accuracy and regulatory validity of such documents as it
      relates to the generated data.  Subcontractor will inform
      Customer as soon as reasonably possible as regards the accuracy and
      regulatory validity of the documents.  The time taken to review
      the documents will be charged back to Customer at the rates detailed in
      the Part A above.

            

    

    
      	
              (c)

            	
              At
      least 21 days prior to filing with the Regulatory Authority any
      documentation which is or is equivalent to the FDA’s Chemistry and
      Manufacturing  Controls (“CMC”) portion of the New Drug
      Application or of the Abbreviated New Drug Application, as the case may
      be, Customer shall provide Subcontractor with a copy of the CMC portion as
      well as all supporting documents which have been relied upon to prepare
      the CMC portion so as to permit Subcontractor to verify that the CMC
      portion accurately describes the Services performed and the manufacturing
      processes to be performed pursuant to this Contract. However, Customer may
      submit certain sections of the CMC section as they are finalized and
      Subcontractor will do its best efforts to verify, as soon as reasonably
      possible, that the described work and manufacturing processes are
      accurate. The time taken to review the documents will be charged back to
      Customer at the rates detailed in the Part A
  above.

            

    

    
      	
              (d)

            	
              If
      Customer does not provide Subcontractor with the documentation requested
      above within the time stipulated and if Subcontractor reasonably believes
      that Subcontractor’s relationship with the Regulatory Authority may be
      jeopardized, Subcontractor may, in its sole discretion, but only to the
      extent that is reasonable, delay or postpone the Regulatory Authority
      inspection which is or is equivalent to the FDA’s pre-approval inspection
      (“PAI”) until such time as Subcontractor has reviewed the requested
      documentation and is satisfied with its
  contents.

            

    

    
      	
              (e)

            	
              If
      in Subcontractor’s sole discretion, acting reasonably, Subcontractor
      determines that any of the information provided by the Customer is
      inaccurate or deficient in any manner whatsoever (the “Deficiencies”),
      Subcontractor shall notify the Customer in writing of such Deficiencies.
      Until such Deficiencies have been resolved or agreement has been reached
      with the Customer for such resolution, Subcontractor reserves the right
      not to participate in the PAI.  In no event, Subcontractor’s
      non-participation in the PAI shall be construed as a Patheon’s breach of
      any of its obligations under this
Contract.

            

    

    
      	
              (f)

            	
              Not
      withstanding the foregoing, a notification of 14 business days will be
      deemed a sufficient notice for an audit or regulatory inspection of the
      Facility, including a PAI.

            

    

    

    9.      
Shipping:

    Shipments
of Customer’s Product shall be made [EXW] (as defined in INCOTERMS
2000) from Facility unless otherwise mutually agreed.  Risk of loss or
of damage to such Product shall transfer to the Customer when the Product is
loaded onto the carrier’s vehicle by Patheon for shipment at the EXW
point.  The Product shall be transported in accordance with the
Customer’s instructions.  Any shipment from Customer to Patheon shall
be made DDP (as per INCOTERMS 2000) the relevant Facility.

    

    10.   Miscellaneous:

    
       A.  
Quality
Agreement

    

    
      	
               
      

            	
              Within
      90 days after the signing of the Tech Transfer Agreement and in any event
      before the start date of manufacture of the first batch of Product, the
      Parties and the Subcontractor shall enter into a Quality Agreement that
      shall include provisions addressing, among other things, each party's
      responsibilities for cGMPs manufacturing and testing of the Product. The
      Quality Agreement shall be prepared in accordance with the European Union
      and U.S. FDA current good manufacturing practice
  standards.

            

    

     B.   Assignment

    
      	
               
      

            	
              Neither
      this Contract, nor any of either party’s rights hereunder, may be assigned
      or otherwise transferred by either party without the prior written consent
      of the other party, which consent shall not be unreasonably
      withheld.

            

    

    
      	
               
      

            	
              Notwithstanding
      the aforementioned it is understood and agreed that Patheon may
      subcontract the Services hereunder to the above mentioned Subcontractor.
      In addition, either party may, without such consent, assign this Agreement
      and its rights or delegate its obligations hereunder to an Affiliate, to
      the purchaser of all or substantially all of its assets related to the
      subject matter of this Agreement or its business, or to its successor
      entity or acquirer in the event of a merger, consolidation or change in
      control of such party, provided that such assignee executes an agreement
      with the non-assigning party hereto whereby it agrees to be bound
      hereunder.

            

    

     

     

    CONFIDENTIAL

     

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 13
of 15

        
          

        

      

      
        
        

      

    

     

    C.   Force
Majeure

    
      	
               
      

            	
              Except
      for payment obligations, neither party will be responsible for delay or
      failure in performance resulting from acts beyond the reasonable control
      and without the fault or negligence of such party, including, but not
      limited to, strikes or other labor disturbances, lockouts, quarantines,
      communicable disease outbreaks, riots, wars, acts of terrorism, fires,
      floods, storms, interruption of or delay in transportation, defective
      equipment, lack of or inability to obtain fuel, power or components or
      compliance with any order or regulation of any government
      entity.

            

    

    
      	
               
      

            	
              D.

            	
              Survival

            

    

    
      	
               
      

            	
              Any
      termination or expiration of this Contract shall not affect any
      outstanding obligations or payments due hereunder prior to such
      termination or expiration, nor shall it prejudice any other remedies that
      the parties may have under this Contract. The Confidentiality Agreement
      and Sections 4, 5, 6, 7 and 8  of the Contract shall survive the
      expiration or termination of this
Contract.

            

    

    E.    Independent
Contractors

    
      	
               
      

            	
              The
      parties are independent contractors and this Contract shall not be
      construed to create between Patheon and the Customer any other
      relationship such as, by way of example only, that of employer-employee,
      principal, agent, joint-venturer, co-partners or any similar
      relationship.

            

    

    
      	
               
      

            	
              F.

            	
              Confidentiality

            

    

    
      	
               
      

            	
              Each
      Party shall keep confidential and shall not use for any purpose other than
      the performance of such Party’s obligations under this Contract, all
      information acquired from the other Party, in connection with this
      Contract and the transactions contemplated hereby, other than any
      information that: (i) is or hereafter becomes generally available to the
      public other than by reason of any default with respect to a
      confidentiality obligation; (ii) was already known to the receiving Party
      as evidenced by prior written documents in the receiving Party’s
      possession; or (iii) is disclosed to the receiving Party by a third party
      who or which is not in default of any confidentiality obligation to the
      disclosing Party (such information to which none of the foregoing
      exceptions applies, “Confidential Information”).  Each receiving
      Party shall transmit Confidential Information only to those of its
      employees, agents, representatives or Affiliates who shall need same for
      the purpose of this Contract and shall take all necessary measures to
      assure that such employees, agents or representatives do not reveal such
      Confidential Information to any third party without prior written
      authorization from the disclosing Party for as long as the receiving Party
      is obliged to hold such information in confidence hereunder, regardless of
      the respective terms of employment of such employees. The confidentiality
      obligations under this Section shall continue for the term of this
      Contract and for 5 years
thereafter.

            

    

    
      G.   Taxes

    

    In the
event that any taxes or duties, of whatever nature, excluding any taxes levied
on profits, income or revenue which are the responsibility of Patheon and /or of
the Subcontractor, are required to be withheld on payments made by Customer
pursuant to this Contract by any state, federal, provincial or foreign
government, including, but not limited to, Value Added Tax, Customer shall be
responsible and promptly pay said taxes and duties to the appropriate taxing
authority without any deduction to any amount owed to Patheon and /or to the
Subcontractor. Customer shall secure and deliver to Patheon upon request any
official receipt for any such taxes paid.

    H.   Other
Terms

    
      	
               
      

            	
              No
      terms, provisions or conditions of any purchase order or other business
      form or written authorization used by Customer or Patheon will have any
      effect on the rights, duties or obligations of the parties, or otherwise
      modify, this Contract, regardless of any failure of Customer or Patheon to
      object to such terms, provisions, or conditions unless such document
      specifically refers to this Contract and is signed by both
      parties.

            

    

    
      	
               
      

            	
              I.

            	
              Insurance

            

    

    
      	
               
      

            	
              Each
      party shall maintain during the term of this Contract general liability
      and product liability insurance.  Either party may request
      evidence of such insurance.

            

    

    J.   
Entire Agreement

    
      	
               
      

            	
              This
      Contract constitutes the complete agreement between the parties with
      respect to this subject matter and supersedes all other prior agreements
      and understandings, whether written or oral. Any modifications, amendment
      or supplement to this Contract must be in writing and signed by authorized
      representatives of both parties.

            

    

    K.   Facsimile

    This Contract may be signed in
counterparts and by facsimile.

    L.   Choice
of Law

    
      	
               
      

            	
              This
      Contract is governed by the laws of the State of New York, without regard
      to any conflicts-of-law principle that directs the application to another
      jurisdiction’s law.  Both parties hereby submit to the exclusive
      jurisdiction of the courts located in New York
  County.

            

    

     

     

    CONFIDENTIAL

     

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 14
of 15

        
          

        

      

      
        
        

      

    

     

    
      M.  
Notices

    

    
      	
               
      

            	
              Any
      notice or other communication required to be given by one party to the
      other under the Contract shall be in writing and shall be deemed to have
      been served: (i) if personally delivered, when actually delivered; or
      (ii) if sent by facsimile, the same day of confirmation receipt of
      transmission; or (iii) if delivered by certified or registered mail
      to the respective addresses of the parties set out below, or to such other
      address or addresses as any of the parties hereto may from time to time in
      writing designate to the other party hereto pursuant to this Section
      10(M):

            

    

    

    
      	
               
      

            	
              If
      to Patheon International A.G.

            

    

    
      	
               
      

            	
              Attention:  General Counsel
      Europe

            

    

    
      	
               
      

            	
              Lindenstrasse
      14,

            

    

    
      	
               
      

            	
              6340
      Baar, Switzerland

            

    

    
      	
               
      

            	
              Facsimile:

            

    

    

    
      	
               
      

            	
              And
      a copy to

            

    

    
      	
               
      

            	
              Attention:  Department
      of Legal Services

            

    

    
      	
               
      

            	
              Viale
      G.B. Stucchi n. 110

            

    

    
      	
               
      

            	
              Monza
      (MI) - Italy

            

    

    
      	
               
      

            	
              Facsimile:
      + 39 039 2027 219

            

    

    

    
      	
               
      

            	 	
              If
      to Customer at:

            

    

    
      	
               
      

            	
              Attention:  Gary
      Gemignani

            

    

    
      	
               
      

            	
              Executive
      Vice President and Chief Financial
Officer

            

    

    
      	
               
      

            	
              45
      Rockefeller Plaza, Suite 2000

            

    

    
      	
               
      

            	
              New
      York, NY  10111

            

    

    
      	
               
      

            	
              Facsimile:
      (212) 332-1667

            

    

    

    
      	
               
      

            	
              And
      a copy to

            

    

    
      	
               
      

            	
              Epstein
      Becker & Green, P.C.

            

    

    c/o Adam So

    250 Park Avenue

    New York,
NY 10177

    Facsimile:
(212) 878-8693

     

     

    CONFIDENTIAL

    
      
        Confidential
treatment has been requested for portions of this exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this exhibit has been filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Act of 1934, as amended.

        
        

      

      
        Page 15
of 15Unassociated Document

     

     

     

    Technical
Agreement for Distribution Services

     

    1.       Contracting
Parties

     

    
      
        
          	
                  Contract
      Giver:

                	 	
                  Gentium
      S.p.A

                
	
                  Name
      and Address:

                	 	
                  Piazza
      XX Settembre, 2

                
	 
      	 	
                  22079
      Villa Guardia, Como

                
	 
      	 	
                  Italy

                

        

      

    

     

     

    (Hereafter
referred to as "Gentium")

     

    
      
        
          	
                  Contract
      Acceptor:

                	 	
                  IDIS
      Limited

                
	
                  Name
      and Address:

                	 	
                  IDIS
      House

                
	 
      	 	
                  Churchfield
      Road

                
	 
      	 	
                  Weybridge

                
	 
      	 	
                  Surrey

                
	 
      	 	
                  KT13
      8DB

                
	 
      	 	
                  United
      Kingdom

                

        

      

    

     

    (Hereafter
referred to as "IDIS")

     

    Terms
used but not defined herein shall have the meanings given to them in the Supply
and Distribution Agreement.

     

    2.       Changes
to this Agreement

    
      
        	
                2.1.  

              	All changes to this agreement must be agreed by both
      parties following written submission by the requesting
  party.

      

       

    

    
      
        
          
            
              
                
                  
                    
                      	
                              No

                            	
                              Details
      of changes / Reason

                            	
                              Date

                            
	
                              1.

                            	 
      	 
      
	
                              2.

                            	 
      	 
      
	
                              3.

                            	 
      	 
      

                    

                  

                

              

            

          

        

      

    

     

    3.       Purpose
of the Agreement

    
      	
              3.1.  

            	
              The
      purpose of this agreement is to describe the technical aspects of the
      storage and the distribution of certain finished products of Gentium
      carried out by IDIS.

            

    

    
      	
              3.2.  

            	
              The
      regulations of this agreement apply to all orders referring to the product
      list (see Schedule 1), which have been agreed upon signing the Technical
      Agreement and before the notice has taken effect. They also apply to
      orders, which have already been given to IDIS on behalf of Gentium, as
      long as they have not yet been carried
out.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              3.3.  

            	
              Gentium
      is responsible for marketing the
product.

            

    

     

    
      	
              4.  

            	
              Basis

            

    

    
      	
              4.1.  

            	
              IDIS
      shall comply with the legal regulations that apply to its area of
      responsibility.

            

    

    
      	
              4.2.  

            	
              IDIS
      is in the possession of a valid wholesale dealer’s license issued by the
      UK Medicines and Healthcare Products Regulatory Agency. IDIS shall
      maintain its systems to support its license. In the event that IDIS loses,
      or is at risk of losing its wholesaler dealer’s license IDIS shall
      immediately notify Gentium.

            

    

    
      	
              4.3.  

            	
              Gentium
      and IDIS appoint responsible contact persons (refer to
      Schedule 2).

            
	 	

              Both
      must inform each other of every amendment to the agreement in writing.
      Amendments are also part of this
agreement.

            

    

    
      	
              4.4.  

            	
              IDIS
      shall implement and update an effective quality management system (QMS),
      including the performance of internal audits and the implementation of the
      resulting corrective actions.

            

    

    
      	
              4.5.  

            	
              IDIS
      shall ensure that all staff affected by this agreement shall be
      appropriately trained with the valid standard operating procedures (SOP)
      and further regulations of Gentium and incorporating any necessary
      amendments into IDIS SOPs which are validated by
  Gentium.

            

    

    
      	
              4.6.  

            	
              IDIS
      shall allow the responsible persons of Gentium to carry out quality
      assurance audits providing reasonable notice has been
    given.

            

    

    
      	
              4.6.1.  

            	
              These
      audits shall be limited in scope to the area’s and systems directly
      related to Gentium’s product.

            

    

     

    
      	
              5.  

            	
              Responsibilities

            

    

    
      	
              5.1.  

            	
              Gentium
      is responsible for:

            

    

    
      	
              5.1.1.  

            	
              Ensuring
      product and packaging elements meet Italian regulatory
      requirements.

            

    

    
      	
              5.1.2.  

            	
              Providing
      IDIS with information relevant for the correct product
      handling

            

    

    5.1.2.1.  All
packaging shall reflect Gentium livery.

    
      	
              5.1.3.  

            	
              Making
      sure that the manufacturer is appropriately
  licensed.

            

    

    
      	
              5.2.  

            	
              IDIS
      is responsible for:

            

    

    
      	
              5.2.1.  

            	
              Complying
      with the cGDP (current Good Distribution Practices) guidelines and
      ensuring that the correct products are delivered to the consignee at the
      right time

            

    

    
      	
              5.2.2.  

            	
              A
      GDP compliant handling of the returned
products

            

    

    
      	
              5.2.3.  

            	
              Implementing
      an effective system for Recall

            

    

    
      	
              5.2.4.  

            	
              Performing
      visual inspection on received goods (e.g. integrity of shipment
      containers, completeness of shipment against shipment documents
      etc.)

            

    

    
      	
              5.2.5.  

            	
              IDIS
      shall inform Gentium of any negative quality or safety issues regarding
      Gentium products should they become aware of
  any.

            

    

    
      	
              5.2.6.  

            	
              Additional
      activities/requirements as defined in the ‘Supply and Distribution
      Agreement’: maintenance of the named patient program database, processes
      of a controlled distribution, and aspects with regard to drug
      safety

            

    

    
      	
              5.2.7.  

            	
              Managing
      drug in line with the process flow in schedule
4

            

    

    
      	
              5.2.8.  

            	
              Reporting
      any received adverse events notifications to Gentium in accordance with
      the process detailed in schedule 5

            

    

     

    
      	
              6.  

            	
              Facilities
      

            

    

    
      	
              6.1.  

            	
              IDIS
      shall manage the warehouse in accordance with GDP as well as storing
      the      Gentium products delivered on
      behalf of Gentium duly.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              6.2.  

            	
              IDIS
      shall protect the Gentium products from damaging impacts and from access
      by unauthorized persons.

            
	 	

              Damaging
      impacts include but are not limited to:

            
	 	

              -
      damaging variations in temperature and humidity

            
	 	

              -
      dust and smell

            
	 	

              -
      animals, insects

            

    

    
      	
              6.3.  

            	
              IDIS
      shall inform Gentium immediately if Gentium products become visibly
      damaged or risk getting visibly
damaged.

            

    

    
      	
              6.4.  

            	
              IDIS
      shall maintain the storage rooms and facilities in accordance with GDP and
      to calibrating measuring instruments (e.g. temperature/humidity loggers)
      on a regular basis in accordance with
GDP.

            

    

    
      	
              6.5.  

            	
              IDIS
      shall keep the storage rooms in an orderly and tidy condition. Cleaning is
      done following a written cleaning
program.

            

    

    
      	
              6.6.  

            	
              IDIS
      shall appoint reliable personnel for the distribution orders, having the
      required theoretical and technical
  qualifications.

            

    

    
      	
              6.7.  

            	
              IDIS
      shall obtain written approval from Gentium if the stored goods are
      transferred into another warehouse other than the one in Unit 3,Canada
      Road, Byfleet, Surrey, United Kingdom. The same applies to changes of
      locations or any change within the warehouse, which may affect the
      storage, and handling of the
products.

            

    

     

    
      	
              7.  

            	
              Product
      Data

            

    

    
      	
              7.1.  

            	
              Gentium
      shall forward IDIS the relevant product data necessary for carrying out
      the tasks well in advance and for keeping IDIS updated with current
      product information should there be any changes or
    amendments

            

    

    
      	
              7.2.  

            	
              IDIS
      shall maintain product related data in line with regulatory
      requirements.

            

    

     

    
      	
              8.  

            	
              Storage,
      Delivery and Transportation

            

    

    
      	
              8.1.  

            	
              The
      handling of processes is defined in the existing QMS of IDIS based on
      SOPs. These are:

            

    

    
      	
              8.1.1.  

            	
              Incoming
      goods: Quarantine, release,
documentation

            

    

    
      	
              8.1.2.  

            	
              Handling
      of quality deficiencies

            

    

    
      	
              8.1.3.  

            	
              Incoming
      and outgoing of goods: According to the FEFO principle (first expiry -
      first out), or the FIFO principle (first in - first out),
      respectively

            

    

    
      	
              8.1.4.  

            	
              Commissioning
      and distribution of products

            

    

    
      	
              8.1.5.  

            	
              Recall
      procedures

            

    

    
      	
              8.1.6.  

            	
              Destruction
      of damaged or expired goods

            

    

    
      	
              8.1.7.  

            	
              Drug
      safety procedures

            

    

    
      	
              8.1.8.  

            	
              Complaint
      handling

            

    

     

    
      	
              9.  

            	
              Duty
      of Information

            

    

    
      	
              9.1.  

            	
              IDIS
      must immediately inform Gentium if:

            

    

    
      	
              9.1.1.  

            	
              An
      inspection by an authority regarding the contracting products is
      announced

            

    

    
      	
              9.1.2.  

            	
              Measures
      are taken by competent authorities regarding Gentium
    products.

            

    

    
      	
              9.1.3.  

            	
              IDIS
      learns about a serious product safety, quality of efficacy
      problem/issue

            

    

    
      
        	
                9.2.  

              	
                Gentium
      must inform IDIS of the supply chain details e.g. site of manufacturer,
      packaging/assembly, storage prior to product arriving at IDIS. This shall
      be listed in Schedule 3

              

      

      
        
          	
                  9.3.  

                	
                  Gentium
      shall provide IDIS with copies of licenses held by Gentium nominated
      manufacturer, packaging/assembly site or storage
  site.

                

        

         

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

         

      

    

    
      	
              10.  

            	
              Confidentiality

            

    

    
      
        	
                10.1
        

              	
                Information
      shared by either party concerning the Products will remain confidential in
      accordance with the Confidentiality Agreement and Supply and Distribution
      Agreement, which shall survive termination of this
    Agreement.

              

      

       

    

    
      
        	
                11.  

              	
                

                  Quality
      Control

                

              

      

      
        
          
            	
                    11.1.
        

                  	
                    

                      Gentium
      shall be responsible for full product testing in accordance with
      their    internal procedures, specifications, methods
      of analysis and any relevant Marketing Authorisation of the Products
      detailed in Schedule 1.

                    

                  

          

          
            
              
                	
                        11.2.   

                      	
                        Gentium
      shall be responsible for forwarding a Certificate of Analysis for each
      batch to IDIS.

                      

              

              
                
                  
                    	
                            11.3.   

                          	
                            Gentium shall be responsible for forwarding a
      Certificate of Compliance for each
      batch to IDIS.

                          

                  

                   

                

              

            

          

        

      

    

    
      	
              12.  

            	
              Sub
      Contracting

            

    

    
       

      
        
          	
                  12.1.
        

                	
                  With
      the exception of courier services, IDIS shall not subcontract any
      activities  of the product without prior consent of
      Gentium.

                

        

         

      

    

    
      	
              13.  

            	
              Table
      of Responsibilities

            

    

     

    
      
        
          
            
              
                
                  	
                          13.1.

                        	
                          Responsibilities

                        	
                          GENTIUM

                        	
                          IDIS

                        
	
                          1

                        	
                          Adverse
      event notification

                        	 
      	
                          X

                        

                

              

            

          

        

      

    

     

    
      
        
          
            
              
                
                  
                    	
                            13.2.

                          	
                            Product
      Data & Quality Control

                          	
                            GENTIUM

                          	
                            IDIS

                          
	
                            1

                          	
                            Transmission
      of product-related logistic

                          	
                            X

                          	 
      
	
                            2

                          	
                            Correct
      handover and maintenance of product data

                          	
                            X

                          	
                            X

                          
	
                            3

                          	
                            Provide
      TSE Certification regarding product status to IDIS

                          	
                            X

                          	 
      
	
                            4

                          	
                            Provide
      Certificate of Analysis for each product batch

                          	
                            X

                          	 
      
	
                            5

                          	
                            Provide
      Certificate of Compliance for each product batch

                          	
                            X

                          	 
      

                  

                

              

            

          

        

      

    

     

    
      
        
          
            
              
                
                  	
                          13.3.

                        	
                          Storage,
      Delivery and Transportation

                        	
                          GENTIUM

                        	
                          IDIS

                        
	
                          1

                        	
                          Delivery
      of products in conformity with the local market as nominated by
      Gentium

                        	 
      	
                          X

                        
	
                          2

                        	
                          Determination
      of the storage conditions and way of shipment

                        	
                          X

                        	 
      
	
                          3

                        	
                          Adherence
      to storage conditions and way of shipment to user

                        	 
      	
                          X

                        
	
                          4

                        	
                          Compliance
      with GDP guidelines

                        	 
      	
                          X

                        
	
                          5

                        	
                          Handling
      of returned goods

                        	 
      	
                          X

                        
	
                          6

                        	
                          Handling
      of technical product complaints

                        	
                          X

                        	
                          X

                        
	
                          7

                        	
                          Recall
      procedures

                        	
                          X

                        	
                          X

                        
	
                          8

                        	
                          Incoming
      goods, control, inventory update

                        	
                          X

                        	
                          X

                        
	
                          9

                        	
                          Adherence
      to FEFO principle

                        	 
      	
                          X

                        
	
                          10

                        	
                          Shipments
      of products

                        	 
      	
                          X

                        
	
                          11

                        	
                          Destruction
      of damaged, returned and expired goods

                        	 
      	
                          X

                        

                

              

            

          

        

      

    

     

    
      
        
          
            
              
                
                  	
                          13.4.

                        	
                          Documentation

                        	
                          GENTIUM

                        	
                          IDIS

                        
	 
      	 
      	
                          X

                        	
                          X

                        

                

              

            

          

        

      

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    IN
WITNESS whereof this Agreement has been entered into the day and year
written.

    
SIGNED
for and on behalf of

    Gentium
S.p.A.

    

    /s/ Gary
Gemignani                                             

    Name:
Gary Gemignani

    Title:  Executive
Vice President and Chief Financial Officer

    Date:
February 26, 2009

    

    

    SIGNED
for and on behalf of

    IDIS
(TRADING AS IDIS LIMITED)

    

    /s/ Maria
Kempshall                                           

    Name:
Maria Kempshall

    Title:    Responsible
Person

    Date:
November 3, 2008

    

    /s/ Tony
Dutta                                                    

    Name:  Tony
Dutta

    Title:     Operations
Director

    Date:
November 6, 2008

     

     

    Schedule
1 – Product List

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Brand
Name:

    

    Generic
Name: Defibrotide

    

    Strength:
200mg

    

    Presentation:
2.5ml ampoule

    

    Form:
Solution                                           

     

    Storage:
Ambient

    

    Pack
size: 10 x 2.5ml ampoules

    

    Therapeutic
Area: Hematology-Oncology

                                                                            

    
      
        

        

      

      Brand
Name: Prociclide

    

    

    Generic
Name: Defibrotide

    

    Strength:
400mg

    

    Presentation: Blister
pack

    

    Form: Capsule                                                      

     

    Storage:
Ambient

    

    Pack
size: 1 x 21

    

    Therapeutic
Area:
Hematology-Oncology                                                                                     

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Schedule
2 – Contact Persons

     

    
      
        
          
            
              
                
                  	
                          Contract
      Acceptor

                        	 	
                          Contract
      Giver

                        
	 	 	 
	
                          Simon
      Estcourt

                          Director
      – Global Market Access

                           

                          IDIS
      House

                          Churchfield
      Road

                          Weybridge

                          Surrey

                          KT13
      8DB

                          United
      Kingdom

                           

                          Telephone
      No: 01932 824000

                          Fax
      No: 01932 824200

                        	 	
                          Tim
      Hillman

                           

                           

                          45
      Rockefeller Plaza

                          Suite
      2000

                          New
      York, NY 10111

                           

                           

                           

                          Telephone
      No: 212-332-1664

                          E-mail
      Address: thillman@gentium.com

                        
	 	 	 
	
                          Maria
      Kempshall

                          Responsible
      Person

                           

                          At
      above address

                           

                          Direct
      Telephone No: 01932 824031

                          Email
      address : mkempshall@idispharma.com

                        	 	
                          Gary
      Gemignani

                           

                          At
      above address

                           

                          Direct
      Telephone No: 212-332-1666

                          Email
      address: ggemignani@gentium.com

                        
	 	 	 
	
                          Karen
      Jessep

                          Supply
      Chain Manager

                           

                          At
      above address

                           

                          Direct
      Telephone No: 01932 824143

                          Email
      address: kjessep@idispharma.com

                           

                        	 	
                          Massimo
      Iacobelli

                           

                           

                          Piazza
      XX Settenbre

                          2,
      22079 Villa Guardia (Como)

                          Italy

                           

                          Direct
      Telephone No: +39 031 385 217

                          Email
      address: miacobelli@gentium.it

                        
	 	 	 
	 
      	 	
                          Salvatore
      Calabrese

                           

                          At
      above address

                           

                          Direct
      Telephone No: +39 031 385 287

                          Email
      address: scalabrese@gentium.it

                        
	 	 	 
	 
      	 	
                          Margaret
      Hoyle

                           

                          At
      above address

                           

                          Direct
      Telephone No: +39 031 385 224

                          Email
      address:
mhoyle@gentium.it

                        

                

              

            

          

        

      

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Schedule
3 – Supply Chain Details

     

    Site of
manufacturer:  Villa Guardia (Co) Italy

     

    Site of
packaging/assembly:  Villa Guardia (Co) Italy

     

    Site of
storage prior to product arriving at IDIS:  Villa Guardia (Co)
Italy

     

    Pack
dimensions:

     

    Contact
for placement of purchase orders:

     

    Bianca
Colombo (bclombo@gentium.it)
+39 031 385 247

    Salvatore
Calabrese (scalabrese@gentium.it)
+39 031 385 287

    Roberta
Grandini (rgrandini@gentium.it)
+39 031 385 421

    Massimo
Iacobelli (miacobelli@gentium.it)  +39
031 385 217

    Margaret
Hoyle (mhoyle@gentium.it)  +39
031 385 224

    Tim
Hillman (thillman@gentium.com)  212-332-1664

    Armando
Cedro (acedro@gentium.it)
+39 031 385 254

     

    Product
lead-time from placement of purchase order:  90 days

     

    Contact
for Invoicing:

     

    Tim
Hillman (thillman@gentium.com)  212-332-1664

    AMMINISTRAZIONE@gentium.it
+39 031 385 417

     

    Contact
for provision of monthly sales report:

     

    Roberta
Grandini (rgrandini@gentium.it)
+39 031 385 421

    Massimo
Iacobelli (miacobelli@gentium.it)  +39
031 385 217

    Tim
Hillman (thillman@gentium.com)  212-332-1664

    Gary
Gemignani (ggemignani@gentium.com)  212-332-1666

    Francesco
Tescione (ftescione@gentium.it)
+39 031 385 222

    Margaret
Hoyle (mhoyle@gentium.it)  +39
031 385 224

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Schedule
4 – Process Flow

     

      

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

      

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Schedule
5 – Pharmacovigilance

     

      

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        
          
            	

                    Gentium
      Pharmacovigilance Representatives

                     

                    Francesco
      Tescione, Ph.D.

                    Drug
      Safety Manager,

                    Medical
      Department

                    TEL:
      +39.031.385.222

                    FAX:
      +39.031.385.241

                    ftescione@gentium.it

                    

                    Massimo
      Iacobelli

                    Senior
      Vice-President, Scientific Director

                    Tele:  +39-031-385-217

                    Mobile:  +39-348-711-2239

                    miacobelli@gentium.it

                     

                     

                     

                  
	

                    IDIS
      Pharmacovigilance Representatives

                    

                    

                    Telephone
      : +44 (0) 1932 824 026

                    

                    Fax
      : +44 (0) 1932 824 226 - FAO Technical Enquiries

                    

                    Email
      :
ps@idispharma.com

                  

          

        

      

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Schedule
6 – Access Form

     

      

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Schedule
7 – Free of Charge Form

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]